Mounjaro side effects: the NHS guidance and what to watch for

The most commonly reported side effects are gastrointestinal: nausea, loose stools, constipation and indigestion, typically at their worst after starting or stepping up a dose.
In January 2026, the MHRA issued a Drug Safety Update singling out acute pancreatitis as a known but infrequent risk with GLP-1 medicines, including tirzepatide, severe stomach pain reaching the back needs urgent attention.
Most side effects are mild-to-moderate and settle within days to around two weeks; they rarely require stopping treatment, but a prescriber should know about anything persistent or distressing.
You can report any suspected side effect (or a suspect seller) directly to the MHRA via the Yellow Card scheme.

Most people starting tirzepatide (Mounjaro) experience some side effects, particularly in the first few weeks. The NHS describes a GI-led profile — nausea, diarrhoea and constipation are the most commonly reported — that tends to ease as your body settles at each dose level. Mounjaro is a prescription-only medicine; a prescriber assesses your full health picture before it's issued, and knowing what to expect matters just as much as knowing when to act.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

What the side-effect picture actually looks like, and when you need to act

The first few weeks: what your body is adjusting to

Picture the evening after your first Mounjaro injection. You've put the pen back in the fridge door and gone about your day, and then (maybe that night, maybe the next morning) your stomach feels unsettled. That's a normal, well-documented response. Tirzepatide slows how quickly food leaves the stomach, and your gut takes time to adapt.

The NHS tirzepatide medicines page lists the very common side effects (affecting more than one in ten people) as nausea, diarrhoea, vomiting, constipation, stomach pain and indigestion. Fatigue, dizziness and headache appear less often. Injection-site reactions (mild redness or itching where the needle went in) are also reported. None of these is a reason to panic, but all of them are worth logging so you can describe them accurately to your prescriber.

The pattern tends to follow dose changes. Symptoms are usually most noticeable in the first few days after a new strength, then fade. By the time the next step-up comes around, most people find they've acclimatised. If nausea is an issue, eating smaller portions and avoiding rich or fatty meals during the adjustment window is practical advice, though your prescriber and the Patient Information Leaflet are the right places to get personalised guidance on managing it.

You can read more about the full side-effect landscape on our detailed Mounjaro side effects page.

When to get medical help, the signs that shouldn't wait

The side effects above are expected. These are not.

Seek urgent medical attention (call 111 or go to A&E) if you develop severe, persistent stomach pain that radiates toward your back, with or without vomiting. This is the presentation associated with acute pancreatitis. In January 2026, the MHRA published a Drug Safety Update specifically flagging pancreatitis as a known but infrequent risk with GLP-1 receptor agonists, tirzepatide included. It's rare, but the pain profile is distinctive and shouldn't be waited out.

Other situations that need prompt attention: signs of an allergic reaction (swelling of the face, throat or tongue, difficulty breathing, severe skin reaction); symptoms suggesting dehydration if you've had severe vomiting or diarrhoea, dizziness when standing, very dark urine, passing very little urine; and persistent gallbladder pain (sharp right-sided or central upper abdominal discomfort, sometimes with yellowing of the skin). Contact your GP or call 111 for any of these. If you want a clearer picture of what to expect before those situations arise, our guide to Mounjaro injection side effects and NHS guidance covers the full range in plain language. In an emergency, call 999.

If you have concerns outside of a medical emergency, the nume support team is available seven days a week, and your prescriber can review whether a side effect warrants a dose pause or any other change.

NHS context: who monitors Mounjaro's safety profile

Mounjaro carries a Black Triangle (▼) designation in the UK, which means the MHRA requires enhanced monitoring while post-marketing safety data continues to accumulate. This is standard for newer medicines and reflects caution, not concern about established safety. The full side-effect and contraindication information is published in the Mounjaro Summary of Product Characteristics on the electronic Medicines Compendium (eMC), that document is what UK prescribers refer to.

Mounjaro is not currently available routinely through a GP for most people; the NHS is rolling it out in phased cohorts. Details of who currently qualifies, and what those NHS phases look like, are covered on our Mounjaro on the NHS page. For those who don't meet the current NHS criteria or prefer not to wait, a private prescription route through a regulated pharmacy is the legal alternative, and our guide to getting Mounjaro through a GP or online explains the difference between those routes clearly. If you're also weighing up the cost and availability across different providers, our comparison of where to buy Mounjaro online in the UK sets out the key differences clearly. For anyone who does qualify through the health service, our page on how to buy Mounjaro through the NHS walks through the process step by step.

The MHRA also runs the Yellow Card scheme, where patients (not just healthcare professionals) can submit reports of suspected side effects. If something unexpected happens on treatment, reporting it contributes to the national safety picture. The link is yellowcard.mhra.gov.uk.

At nume, our prescribers go through every aspect of side-effect risk with you as part of the consultation, and they're reachable afterwards if something concerns you. If you'd like to talk through whether Mounjaro is suitable for your health picture, check your eligibility with a free consultation.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions